Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H. Shear, Keith A. Betts, Ahmed M. Soliman, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 3, pp. 572-581
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 22
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 8, pp. 1777-1792
Open Access | Times Cited: 41
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
Yamin Shu, Jing Chen, Yiling Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 27
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis
Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 4, pp. 409-409
Closed Access | Times Cited: 9
Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis
XueQing Hu, Cong Qi, Fang Feng, et al.
Phytomedicine (2022) Vol. 105, pp. 154384-154384
Closed Access | Times Cited: 33
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 38
Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis
Xuân‐Lan Lam Hoai, Thierry Simonart
Journal of Clinical Medicine (2023) Vol. 12, Iss. 16, pp. 5410-5410
Open Access | Times Cited: 14
Naturally derived bioactive compounds as precision modulators of immune and inflammatory mechanisms in psoriatic conditions
Andrei-Flavius Radu, Delia Mirela Ţiț, Laura Endres, et al.
Inflammopharmacology (2024)
Open Access | Times Cited: 5
Nail psoriasis and nail lichen planus: Updates on diagnosis and management
Jonathan K. Hwang, Chander Grover, Matilde Iorizzo, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 3, pp. 585-596
Closed Access | Times Cited: 13
Jianpi-Yangxue-Jiedu decoction improves the energy metabolism of psoriasis mice by regulating the electron transfer of oxidative phosphorylation
Ning Zhao, YaZhuo Wang, BaoQuan Qu, et al.
Journal of Ethnopharmacology (2024) Vol. 324, pp. 117714-117714
Closed Access | Times Cited: 4
Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors—Literature Review and Statement of Experts from Polish Dermatological Society
Joanna Narbutt, Zbigniew Żuber, Aleksandra Lesiak, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 82-82
Open Access | Times Cited: 4
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden
Paolo Dapavo, Martina Burlando, Claudio Guarneri, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 133-138
Open Access | Times Cited: 4
Treatment of Nail Psoriasis
Jonathan K. Hwang, Shari R. Lipner
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 387-398
Closed Access | Times Cited: 4
Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis
Wentao Shi, Ziyi Zhao, Yinghong Zhai, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 186-186
Open Access | Times Cited: 3
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
Edinson López, Raúl Cabrera, Cristóbal Lecaros
Anais Brasileiros de Dermatologia (2024) Vol. 99, Iss. 4, pp. 546-567
Open Access | Times Cited: 3
Anti‐ROS and NIR‐II‐Responsive Hyaluronic Acid Microneedle Loaded With Baicalin Nanoparticles for Treatment of Psoriasis
Chuanlan Xia, Xinwei Fu, Qi Wang, et al.
Macromolecular Rapid Communications (2024) Vol. 45, Iss. 15
Closed Access | Times Cited: 3
Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Ryan Fan, Jeffrey M. Cohen
PubMed (2022) Vol. 95, Iss. 2, pp. 249-255
Closed Access | Times Cited: 14
Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
Yu Chen, Songmei Geng, Bin Yang, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 10, pp. 1190-1198
Open Access | Times Cited: 2
Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis
Konstantinos Ouranos, Hira Saleem, Stephanos P. Vassilopoulos, et al.
Inflammatory Bowel Diseases (2024) Vol. 31, Iss. 1, pp. 37-51
Closed Access | Times Cited: 2
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
Richard B. Warren, Kerry Donnelly, Sandeep Kiri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 3133-3147
Open Access | Times Cited: 2
Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality
Robin Guelimi, Sivem Afach, Jean-Philippe Régnaux, et al.
British Journal of Dermatology (2021) Vol. 187, Iss. 1, pp. 29-41
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top